יתרונות כלכליים

Health Economic Benefits

In a study carried out at a UK general hospital which showed that use of Parafricta garments reduced the incidence of decubitus ulcers by 16% a health economic model estimated that the savings per 100 at risk patients was £63,000 and equating to annual savings in the entire hospital of £420,000.  The model takes account of the fact that patients with ulceration occupy beds for longer and require additional intervention and wound dressings (Smith and Ingram 2010).Following introduction of Parafricta bootees in 6 high risk wards at a major NHS Trust in England the annual incidence of grade 2 heel ulcers was reduced by 32%, representing significant  annual treatment savings (reported at EPUAP 2013). Routine adoption of the bootees in all wards is expected to deliver further health economic benefits.

The NHS in England directly incentivises success in reducing the incidence of Pressure Ulcers through its CQUIN payment framework.  The NHS Safety Thermometer includes Pressure Ulcer incidence as one of its key measures of outcomes and therefore entitlement to CQUIN payments.  Prevalence of grade 2 ulcers alone has been reported according to the latest data gathered from the NHS Safety Thermometer to be 3%.  The cost of treating grade 2 ulcers has been estimated at £47 per day for uncomplicated cases (Dealey and Posnett 2012).  See references.  Daily treatment of grade 2 ulcers alone in a 650 bed hospital would therefore cost £917 and the annual cost amount to £335,000.  The annual cost of treating deeper ulcers or complications of ulcers would add significant amounts to this total.  The treatment of ulcers in care homes and patients own homes adds a significant further cost to the NHS, mostly through additional district nurse visits.

The cost-benefit case for using Parafricta garments to help reduce the costs of treating pressure ulcers in England is currently the subject of a Medical Technologies Evaluation Programme assessment by the National Institute for Health and Care Excellence (NICE) – expected to report in November 2014.